The protective role of statins in COVID-19 patients: a retrospective observational study.

Translational medicine communications Pub Date : 2021-01-01 DOI:10.1186/s41231-021-00102-4

Srikanth Umakanthan, Sanjum Senthil, Stanley John, Mahesh K Madhavan, Jessica Das, Sonal Patil, Ragunath Rameshwaram, Ananya Cintham, Venkatesh Subramaniam, Madhusudan Yogi, Abhishek Bansal, Sumesh Achutham, Chandini Shekar, Vijay Murthy, Robbin Selvaraj

{"title":"The protective role of statins in COVID-19 patients: a retrospective observational study.","authors":"Srikanth Umakanthan, Sanjum Senthil, Stanley John, Mahesh K Madhavan, Jessica Das, Sonal Patil, Ragunath Rameshwaram, Ananya Cintham, Venkatesh Subramaniam, Madhusudan Yogi, Abhishek Bansal, Sumesh Achutham, Chandini Shekar, Vijay Murthy, Robbin Selvaraj","doi":"10.1186/s41231-021-00102-4","DOIUrl":null,"url":null,"abstract":"Background: To evaluate and determine the protective role of statins in COVID-19 patients.Methods: This is a retrospective cohort study conducted across five hospitals in India. Patients diagnosed with COVID-19 and hospitalized with existing and valid medical documentation were included.Results: This study comprised 3252 COVID-19 patients, of whom 1048 (32.2%) were on statins, with 52.4% being males. The comorbidity prevalence of hypertension was 75%, followed by diabetes 62.51% and coronary artery disease being 47.5%. At the time of hospitalization, statin users had a higher incidence of dyspnea, cough, and fatigue (95.8, 93.3, and 92.7%). The laboratory results revealed a lower mean of WBC count (7.8 × 103/μL), D-dimer (2.4 μg/mL), and C-reactive protein (103 mg/L) among statin users. They also had lower mortality rates (17.1%), a lesser requirement for mechanical ventilation (20%), and hemodialysis (5.4%).Conclusion: This observation study elaborates on the beneficial effects of statins in COVID-19 patients. However, the inferences from this study should be viewed with caution due to the impending effect of confounding factors on its statistical results.","PeriodicalId":75244,"journal":{"name":"Translational medicine communications","volume":"6 1","pages":"22"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475829/pdf/","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational medicine communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41231-021-00102-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 17

Abstract

Background: To evaluate and determine the protective role of statins in COVID-19 patients.

Methods: This is a retrospective cohort study conducted across five hospitals in India. Patients diagnosed with COVID-19 and hospitalized with existing and valid medical documentation were included.

Results: This study comprised 3252 COVID-19 patients, of whom 1048 (32.2%) were on statins, with 52.4% being males. The comorbidity prevalence of hypertension was 75%, followed by diabetes 62.51% and coronary artery disease being 47.5%. At the time of hospitalization, statin users had a higher incidence of dyspnea, cough, and fatigue (95.8, 93.3, and 92.7%). The laboratory results revealed a lower mean of WBC count (7.8 × 10³/μL), D-dimer (2.4 μg/mL), and C-reactive protein (103 mg/L) among statin users. They also had lower mortality rates (17.1%), a lesser requirement for mechanical ventilation (20%), and hemodialysis (5.4%).

Conclusion: This observation study elaborates on the beneficial effects of statins in COVID-19 patients. However, the inferences from this study should be viewed with caution due to the impending effect of confounding factors on its statistical results.

Abstract Image

查看原文本刊更多论文

他汀类药物对COVID-19患者的保护作用:一项回顾性观察研究

背景:评价和确定他汀类药物在COVID-19患者中的保护作用。方法:这是一项在印度五家医院进行的回顾性队列研究。纳入了诊断为COVID-19并有现有有效医疗文件住院的患者。结果:本研究共纳入3252例COVID-19患者，其中1048例(32.2%)使用他汀类药物，男性占52.4%。合并症高血压占75%，其次为糖尿病62.51%，冠状动脉疾病占47.5%。在住院时，他汀类药物使用者有更高的呼吸困难、咳嗽和疲劳发生率(95.8、93.3和92.7%)。实验室结果显示，他汀类药物服用者白细胞计数(7.8 × 103/μL)、d -二聚体(2.4 μg/mL)和c反应蛋白(103 mg/L)的平均值较低。他们的死亡率也较低(17.1%)，机械通气需求较低(20%)，血液透析需求较低(5.4%)。结论:本观察研究阐述了他汀类药物在COVID-19患者中的有益作用。然而，由于混杂因素对统计结果的影响，本研究的推论应谨慎看待。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational medicine communications

自引率

0.00%

发文量

审稿时长

5 weeks